Welcome to our dedicated page for Shoulder Innovations SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Shoulder Innovations, Inc. (NYSE: SI) provide detailed regulatory information about the company’s operations as a commercial-stage medical technology business focused on shoulder surgical care. These documents include current reports on Form 8-K that describe material events such as quarterly financial results and key corporate announcements.
Recent Forms 8-K furnished by Shoulder Innovations cover financial results for quarters ended June 30 and September 30, 2025. In these filings, the company provides net revenue, gross margin, operating loss, net loss and related financial data, along with discussions of factors affecting performance. The filings also reference non-GAAP measures such as Adjusted EBITDA and explain how these metrics are calculated and their limitations.
Other 8-K filings document significant corporate developments. For example, the company has furnished press releases announcing its initial public offering and convertible notes financing, as well as a strategic partnership with Interventional Systems to introduce a shoulder-specific micro-robotic solution that is expected to integrate with the ProVoyance platform. These filings help investors track how Shoulder Innovations is expanding its ecosystem of advanced implant systems, enabling technologies and instrument systems for shoulder arthroplasty.
On Stock Titan’s SEC filings page, users can access these reports as they are made available through the EDGAR system. AI-powered tools can assist in summarizing lengthy filings, highlighting items such as revenue trends, operating results, non-GAAP reconciliations and descriptions of material agreements or partnerships. Users can also review filing exhibits, including earnings press releases and, where provided, conference call transcripts furnished as exhibits to Form 8-K.
Together, the SEC filings for SI offer a structured view of Shoulder Innovations’ financial reporting, regulatory disclosures and significant events related to its focus on the shoulder surgical care market.
Shoulder Innovations, Inc. officer David Lawrence Blue reported buying common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,041 shares of common stock at $12.16 per share, a price set at 85% of the closing price that day under the ESPP rules. After this transaction, he beneficially owned 139,372 shares, held directly. Blue serves as the company’s Chief Customer Experience Officer, and the filing notes that this is a voluntary report of the ESPP purchase.
Shoulder Innovations, Inc. CEO & Executive Chairman Robert Joseph Ball reported acquiring additional common stock through the company’s 2025 Employee Stock Purchase Plan. On December 31, 2025, he acquired 1,661 shares of common stock at a purchase price of $12.16 per share, which the plan set at 85% of the closing price of the company’s common stock on that date. Following this ESPP purchase, Ball beneficially owned 120,118 shares of Shoulder Innovations common stock held directly.
Shoulder Innovations, Inc. director and Chief Operating Officer Matthew Fraser Ahearn reported acquiring common stock through the company’s 2025 Employee Stock Purchase Plan (ESPP). On December 31, 2025, he acquired 477 shares of common stock at a purchase price of $12.16 per share, which the ESPP sets at 85% of the closing price of the stock on that date. Following this transaction, he beneficially owned 215,856 shares of Shoulder Innovations common stock in direct ownership.
Shoulder Innovations, Inc. Chief Financial Officer Jeffrey S. Points reported acquiring additional company stock. On 12/11/2025 he acquired 995 common shares at $14.65 per share, and on 12/12/2025 he acquired 1,005 shares at $14.98. Following these transactions, he directly owned 54,445 common shares. He also reported indirect beneficial ownership of 50 shares held by his son.
Shoulder Innovations, Inc.'s CEO and Executive Chairman, who also serves as a director, reported purchasing additional common stock. On December 11, 2025, the insider bought 3,300 shares at a weighted average price of
Shoulder Innovations, Inc. reported that it has entered into a strategic partnership with Interventional Systems to bring a robotic platform to shoulder arthroplasty procedures. The collaboration aims to pair Shoulder Innovations’ implant and surgical know-how with Interventional Systems’ robotics technology to support more precise shoulder replacement surgery. The news was shared through a press release furnished under a current report, meaning it provides an operational and strategic update rather than new financial results.
Shoulder Innovations, Inc. received a Schedule 13G reporting significant ownership by Lightstone-affiliated entities. LSV Associates II, LLC, together with Lightstone Ventures II, L.P. and Lightstone Ventures II (A), L.P., reported beneficial ownership of 1,885,136 shares of common stock, representing 9.3% of the class as of September 30, 2025. The filing notes the Reporting Persons expressly disclaim status as a group.
Within the total, Lightstone Ventures II, L.P. holds 1,781,479 shares (8.7%) and Lightstone Ventures II (A), L.P. holds 103,657 shares (0.5%). Percentages are based on 20,359,960 shares outstanding as of September 3, 2025. LSV Associates II serves as general partner and has voting and investment authority; Michael A. Carusi, Jean George, and Henry A. Plain Jr. share voting and investment authority over the same 1,885,136 shares.
Shoulder Innovations, Inc. received a Schedule 13G reporting significant beneficial ownership by entities affiliated with U.S. Venture Partners and Casey M. Tansey as of the event date 09/30/2025.
U.S. Venture Partners XII, L.P. reports beneficial ownership of 1,686,403 shares of common stock, representing 8.2%, with shared voting and dispositive power over those shares. Presidio Management Group XII, L.L.C. reports 2,693,121 shares (13.1%) with shared voting and dispositive power. Casey M. Tansey reports an aggregate 2,740,787 shares (13.3%), including 47,666 shares with sole voting and dispositive power and 2,693,121 shares with shared power.
Percentages are based on 20,601,684 shares outstanding as of November 5, 2025, as reported by the company in its Form 10-Q filed November 12, 2025.
Shoulder Innovations, Inc. received a Schedule 13G from cultivate(MD) Holdings, LLC and affiliated individuals disclosing beneficial ownership of 1,363,394 shares of common stock, representing 6.7% of the class as of 09/30/2025.
The filing attributes the shares to four investment vehicles: CMD I (185,623 shares), CMD II (309,948), Genesis Investment Holdings (592,585), and CMD Accelerator (275,238). cultivate(MD) Holdings is the general partner or manager of these entities and is described as having voting and dispositive power over their holdings. Directors David Lawrence Blue, Matthew Fraser Ahearn, Robert Joseph Ball, and managing director R. Sean Churchill are listed as Reporting Persons and disclaim beneficial ownership except to the extent of any pecuniary interest.
Shoulder Innovations, Inc. reported third‑quarter results, highlighting rapid growth and strengthened liquidity following its IPO. Net revenue reached $11.8 million for the quarter, up 57.7% from a year ago, as more implant systems were sold. Gross profit was $9.0 million with a 76.2% gross margin. The company posted a net loss of $8.7 million, reflecting higher commercial, legal, and public‑company costs.
The balance sheet expanded after the IPO. As of September 30, 2025, cash and cash equivalents were $54.9 million and marketable securities were $82.4 million. Total liabilities were $29.9 million, including long‑term debt of $14.8 million, and stockholders’ equity was $147.8 million. Operating cash outflow for the nine months was $19.8 million, offset by $147.0 million provided by financing activities.
On August 1, 2025, the company closed its IPO, issuing 5,000,000 shares at $15.00 per share for approximately $64.2 million in net proceeds. Immediately before closing, all preferred shares and $40.0 million of convertible notes converted into common stock, simplifying the capital structure and increasing the public float.